Form 4: Acrivon Therapeutics Executives Report Changes in Beneficial Ownership
SEC Form 4 Filing
Acrivon Therapeutics' President/CEO Peter Blume-Jensen and EVP Kristina Masson report changes in their beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.
Summary
- Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, and Kristina Masson, EVP, reported changes in their beneficial ownership of Acrivon Therapeutics stock on February 21, 2025.
- The changes are due to shares withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- Blume-Jensen disposed of 19,904 shares at a price of $5.54, leaving him with 2,285,781 directly owned shares.
- Masson indirectly owns 316,177 shares.
- Both Blume-Jensen and Masson have disclaimed beneficial ownership of the shares held by their spouse, except to the extent of their pecuniary interest.
Sentiment
Score: 5
Explanation: This is a neutral filing related to routine tax obligations. It doesn't indicate positive or negative sentiment regarding the company's performance or future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard tax-related stock transactions and doesn't necessarily reflect a change in the executives' long-term outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 02/21/2025 | Date of transaction involving the disposal of shares for tax withholding. |
| 02/25/2025 | Date of signature for the Form 4 filings by Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen and Kristina Masson. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.